NuCana plc Presents New Clinical Data
Ticker: NCNA · Form: 6-K · Filed: Dec 10, 2025 · CIK: 1709626
| Field | Detail |
|---|---|
| Company | Nucana PLC (NCNA) |
| Form Type | 6-K |
| Filed Date | Dec 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-data, press-release, routine-filing
TL;DR
NuCana dropped new clinical data on Dec 10th. Check it out.
AI Summary
On December 10, 2025, NuCana plc announced the presentation of new clinical data from patients treated with their drug. The press release was filed as a Form 6-K with the SEC.
Why It Matters
This filing indicates NuCana plc is actively sharing progress on its drug development, which could impact investor sentiment and future clinical trial directions.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) providing an update on clinical data presentation, not a material event like a merger or significant financial change.
Key Players & Entities
- NuCana plc (company) — Registrant
- December 10, 2025 (date) — Date of press release and filing
FAQ
What specific clinical data was presented by NuCana plc?
The filing states that NuCana plc presented the 'latest clinical data from patients' but does not specify the exact nature or results of this data.
What is the purpose of this Form 6-K filing?
This Form 6-K is filed by NuCana plc to report the issuance of a press release announcing the presentation of clinical data.
When was the press release announcing the clinical data presentation issued?
The press release was issued on December 10, 2025.
Where is NuCana plc's principal executive office located?
NuCana plc's principal executive office is located at 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom.
Does NuCana plc file annual reports on Form 20-F or Form 40-F?
NuCana plc indicates that it files annual reports on Form 20-F.
Filing Stats: 344 words · 1 min read · ~1 pages · Grade level 15.8 · Accepted 2025-12-10 08:15:43
Filing Documents
- d23141d6k.htm (6-K) — 10KB
- d23141dex991.htm (EX-99.1) — 13KB
- 0001193125-25-313499.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NuCana plc By: /s/ Ian Webster Name: Ian Webster Title: Interim Chief Financial Officer (Principal Financial and Accounting Officer) Date: December 10, 2025